1. Oncostatin M, a novel profibrogenic mediator, is involved in the progression non-alcoholic fatty liver disease and stimulates migration of myofibroblasts. (February 2020) Authors: Foglia, B.; Novo, E.; Sutti, S.; Cannito, S.; Protopapa, F.; Bocca, C.; Maggiora, M.; Rosso, C.; Bugianesi, E.; Albano, E.; Parola, M. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The CCAAT/Enhancer-Binding Protein beta - SerpinB3 axis inhibition as a novel strategy for Non-Alcoholic Steatohepatitis treatment. (March 2023) Authors: Martini, A.; Villano, G.; Novo, E.; Turato, C.; Quarta, S.; Ruvoletto, M.; Biasiolo, A.; Protopapa, F.; Chinellato, M.; Trevellin, E.; Granzotto, M.; Cannito, S.; Cendron, L.; De Siervi, S.; Guido, M.; Parola, M.; Vettor, R.; Pontisso, P. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗